Phenotypes associated with this allele

• Allele Symbol: Tg(Myh6/tetO-PRKCA*)1Jmk
• Allele Name: transgene insertion 1, Jeffery D Molkentin
• Allele ID: MGI:3851565
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(Myh6-tTA)55Rbns/0 Tg(Myh6/tetO-PRKCA*)1Jmk/0	involves: FVB/N	MGI:3851897

Genotype
MGI:3851897

cx1

• Allelic Composition: Tg(Myh6-tTA)55Rbns/0; Tg(Myh6/tetO-PRKCA*)1Jmk/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

abnormal myocardium layer morphology ( J:132098 )

• induced mice show equivalent infarcted area/area at risk ratio to wild-type after myocardial infarction

increased heart weight ( J:132098 )

• by 16 weeks after MI, wild-type mice show significant increases in heart weight/body weight ratios, but induced mutants exhibit partial protection from changes

abnormal cardiac muscle contractility ( J:132098 )

• induced mice show greater fractional shortening (%) than wild-type up to 3 weeks after myocardial infarction (MI)

increased heart ventricle muscle contractility ( J:132098 )

• induced adult mice (no doxycycline) showed increased contractility at baseline and with dobutamine infusion compared with wild-type mice; mutant mice treated with doxycycline show no increased contractility compared to wild-type

• by 12 and 16 weeks after MI, induced mice show reduced ventricular performance similar to wild-type with MI

• induced mice show greater fractional shortening (%) than wild-type up to 3 weeks after myocardial infarction (MI)

• after experimental myocardial infarction (MI), uninduced mice (doxycycline treated) showed decreased ventricular function whereas mice without doxycycline (induced) show partial protection against functional performance deficits at 1 and 2 weeks following MI

muscle

abnormal myocardium layer morphology ( J:132098 )

• induced mice show equivalent infarcted area/area at risk ratio to wild-type after myocardial infarction

abnormal cardiac muscle contractility ( J:132098 )

• induced mice show greater fractional shortening (%) than wild-type up to 3 weeks after myocardial infarction (MI)

increased heart ventricle muscle contractility ( J:132098 )

• induced adult mice (no doxycycline) showed increased contractility at baseline and with dobutamine infusion compared with wild-type mice; mutant mice treated with doxycycline show no increased contractility compared to wild-type

• by 12 and 16 weeks after MI, induced mice show reduced ventricular performance similar to wild-type with MI

• induced mice show greater fractional shortening (%) than wild-type up to 3 weeks after myocardial infarction (MI)

• after experimental myocardial infarction (MI), uninduced mice (doxycycline treated) showed decreased ventricular function whereas mice without doxycycline (induced) show partial protection against functional performance deficits at 1 and 2 weeks following MI

growth/size/body

increased heart weight ( J:132098 )

• by 16 weeks after MI, wild-type mice show significant increases in heart weight/body weight ratios, but induced mutants exhibit partial protection from changes